

Freedom of Information Request	FOI 23-077	2 nd March 2023
--------------------------------	------------	----------------------------

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ozanimod**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**

The Health Board is unable to provide information on the number of patients treated with specific drugs, however, please find below the quantities dispensed, across Health Board pharmacies for 'gastroenterology only for any medical condition' for the period November 2022 – January 2023:

Description	Quantity
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	805
ADALIMUMAB (AMGEVITA) 40 mg in 0.8mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	6
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack	22
INFLIXIMAB (FLIXABI) 100 mg Intravenous Infusion 1 Vial Pack	1374
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack	22
TOFACITINIB 5 mg Tablets 56 Tablet Pack	9
USTEKINUMAB 130 mg in 26mL Intravenous Infusion 1 Vial Pack	19
USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	112
VEDOLIZUMAB 108 mg in 0.68mL Pre-Filled Pen 1 Pre-Filled Pen Pack	634

Description	Quantity
VEDOLIZUMAB 108 mg in 0.68mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	8
VEDOLIZUMAB 300 mg Intravenous Infusion 1 Vial Pack	254

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**

Please refer to Q1.